KCKun-Mao Chao

Kun-Mao Chao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kun-Mao Chao has a total of 155 co-authors. Here are the top co-authors by number of shared publications:

  • Hsiao-Fei Liu

    Department of Computer Science and Information Engineering, National Taiwan University, Taipei, Taiwan 106, Taiwan

    9 shared publications
  • Kuan-Yu Chen

    Department of Computer Science and Information Engineering, National Taiwan University, Taipei 106, Taiwan

    9 shared publications
  • Bang Ye Wu

    Department of Computer Science and Information Engineering, National Chung Cheng University, Min-Hsiung, Chiayi, 621, Taiwan

    8 shared publications
  • Chih-Hsin Lee

    Division of Pulmonary Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

    7 shared publications
  • Jann-Yuan Wang

    Department of Internal Medicine, National Taiwan University Hospital

    7 shared publications
  • Webb Miller

    Department of Computer Science and Engineering, The Pennsylvania State University, University Park PA 16802, USA

    7 shared publications

Latest Publications

  • Open Access

    Facilitated and Controlled Strontium Ranelate Delivery Using GCS-HA Nanocarriers Embedded into PEGDA Coupled with Decortication Driven Spinal Regeneration

    by Chih-Wei Chiang, Chih-Hwa Chen, Yankuba B Manga, Shao-Chan Huang, Kun-Mao Chao, Pei-Ru Jheng, Pei-Chun Wong, Batzaya Nyambat, Mantosh Kumar Satapathy, Er-Yuan Chuang

    Background and Purpose: Strontium ranelate (SrR) is an oral pharmaceutical agent for osteoporosis. In recent years, numerous unwanted side effects of oral SrR have been revealed. Therefore, its clinical administration and applications are limited. Hereby, this study aims to develop, formulate, and characterize an effective SrR carrier system for spinal bone regeneration. Methods: Herein, glycol chitosan with hyaluronic acid (HA)-based nanoformulation was used to encapsulate SrR nanoparticles (SrRNPs) through electrostatic interaction. Afterward, the poly(ethylene glycol) diacrylate (PEGDA)-based hydrogels were used to encapsulate pre-synthesized SrRNPs (SrRNPs-H). The scanning electron microscope (SEM), TEM, rheometer, Fourier-transform infrared spectroscopy (FTIR), and dynamic light scattering (DLS) were used to characterize prepared formulations. The rabbit osteoblast and a rat spinal decortication models were used to evaluate and assess the developed formulation biocompatibility and therapeutic efficacy. Results: In vitro and in vivo studies for cytotoxicity and bone regeneration were conducted. The cell viability test showed that SrRNPs exerted no cytotoxic effects in osteoblast in vitro. Furthermore, in vivo analysis for new bone regeneration mechanism was carried out on rat decortication models. Radiographical and histological analysis suggested a higher level of bone regeneration in the SrRNPs-H-implanted groups than in the other experimental groups. Conclusion: Local administration of the newly developed formulated SrR could be a promising alternative therapy to enhance bone regeneration in bone-defect sites in future clinical applications.


  • Open Access

    Data-driven interdisciplinary mathematical modelling quantitatively unveils competition dynamics of co-circulating influenza strains

    by Bin-Shenq Ho, Kun-Mao Chao

    Co-circulation of influenza strains is common to seasonal epidemics and pandemic emergence. Competition was considered involved in the vicissitudes of co-circulating influenza strains but never quantitatively studied at the human population level. The main purpose of the study was to explore the competition dynamics of co-circulating influenza strains in a quantitative way. We constructed a heterogeneous dynamic transmission model and ran the model to fit the weekly A/H1N1 influenza virus isolation rate through an influenza season. The construction process started on the 2007–2008 single-clade influenza season and, with the contribution from the clade-based A/H1N1 epidemiological curves, advanced to the 2008–2009 two-clade influenza season. Pearson method was used to estimate the correlation coefficient between the simulated epidemic curve and the observed weekly A/H1N1 influenza virus isolation rate curve. The model found the potentially best-fit simulation with correlation coefficient up to 96% and all the successful simulations converging to the best-fit. The annual effective reproductive number of each co-circulating influenza strain was estimated. We found that, during the 2008–2009 influenza season, the annual effective reproductive number of the succeeding A/H1N1 clade 2B-2, carrying H275Y mutation in the neuraminidase, was estimated around 1.65. As to the preceding A/H1N1 clade 2C-2, the annual effective reproductive number would originally be equivalent to 1.65 but finally took on around 0.75 after the emergence of clade 2B-2. The model reported that clade 2B-2 outcompeted for the 2008–2009 influenza season mainly because clade 2C-2 suffered from a reduction of transmission fitness of around 71% on encountering the former. We conclude that interdisciplinary data-driven mathematical modelling could bring to light the transmission dynamics of the A/H1N1 H275Y strains during the 2007–2009 influenza seasons worldwide and may inspire us to tackle the continually emerging drug-resistant A/H1N1pdm09 strains. Furthermore, we provide a prospective approach through mathematical modelling to solving a seemingly unintelligible problem at the human population level and look forward to its application at molecular level through bridging the resolution capacities of related disciplines.


  • Maximum-Sum Segments

    by Kun-Mao Chao

  • Open Access

    Mycobacterium tuberculosis nucleic acid amplification tests reduce nosocomial tuberculosis exposure in intensive care units: A nationwide cohort study

    by Jann‐Yuan Wang, Ming‐Chia Lee, Jer‐Hwa Chang, Ming‐Chih Yu, Vin‐Cent Wu, Kuo‐Liang Huang, Chiu‐Ping Su, Kun‐Mao Chao, Chih‐Hsin Lee

    Background and objective: This retrospective national surveillance study investigated the burden of and risk factors for nosocomial exposure of pulmonary tuberculosis (TB) in intensive care units.Methods: Patients admitted to intensive care units were identified from the National Health Insurance Research Database. During 2004–2009, there were 1 387 707 intensive care unit admissions of 900 562 adult patients. Pulmonary tuberculosis association was considered if the patient was diagnosed with pulmonary tuberculosis during admission or within 3 months after discharge. Nosocomial transmissible period was calculated based on the length of anti‐tuberculosis treatment and negative‐pressure isolation during admission.Results: Pulmonary tuberculosis was associated with 1.20% of all intensive care unit admissions and 6731 (38.9%) started anti‐TB treatment during admission. For the other 10 583 admissions, the diagnosis was made after discharge and anti‐TB treatment was not prescribed during admission. The probability paralleled the regional tuberculosis incidence. On average, 2794 pulmonary tuberculosis associated intensive care unit admissions contributed to 42 999–44 062 days of nosocomial exposure per year. The length of nosocomial transmissible period decreased with the gradual implementation of Mycobacterium tuberculosis nucleic acid amplification tests in intensive care practice. Multivariate linear regression analysis revealed that the length of nosocomial transmissible period was inversely associated with male gender, airway symptoms prior to admission and performing M. tuberculosis nucleic acid amplification tests and mycobacterial culture.Conclusions: Nosocomial tuberculosis exposure is not uncommon in intensive care units. Performing rapid molecular diagnostic tests in those suspected of tuberculosis is recommended to reduce the risk of nosocomial exposure.


  • Open Access

    Maximum-Sum Segments

    by Kun-Mao Chao

  • Open Access

    Optimal Duration of Anti-TB Treatment in Patients With Diabetes

    by Jann-Yuan Wang, Ming-Chia Lee, Chin-Chung Shu, Chih-Hsin Lee, Li-Na Lee, Kun-Mao Chao, Feng-Yee Chang